Repurposing of Bromocriptine for Cancer Therapy [PDF]
Frontiers in Pharmacology, 2018 Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Ean-Jeong Seo +3 more
doaj +2 more sources
Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases [PDF]
American Journal of Perinatology Reports, 2018 Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.
Rebecca Simon +2 more
doaj +2 more sources
Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
Translational Oncology, 2023 Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in patients who have failed ...
Lijuan Bai +15 more
doaj +2 more sources
The impact of vaginal bromocriptine on reducing pain and menstrual bleeding in women with adenomyosis: a randomized controlled trial [PDF]
Scientific ReportsBromocriptine, a dopamine receptor agonist that suppresses prolactin secretion from the pituitary gland, is an inexpensive and widely accessible medication with few adverse effects.
Parvin Hakimi +3 more
doaj +2 more sources
Bromocriptine and insulin sensitivity in lean and obese subjects
Endocrine Connections, 2016 Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler +6 more
doaj +2 more sources
Impact of bromocriptine withdrawal timing on pregnancy outcomes in patients with pituitary prolactin-secreting microadenomas: a real-world retrospective study of 188 pregnancies in China [PDF]
Frontiers in PharmacologyBackgroundThis study aims to evaluate the influence of the timing for bromocriptine withdrawal in pregnant women with pituitary prolactin-secreting microadenomas.MethodsIn this retrospective study,188 pregnant women diagnosed with pituitary prolactin ...
Jiao Lan +14 more
doaj +2 more sources
Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis [PDF]
Cancer Cell International, 2007 Background Prolactinoma is the most frequent pituitary tumor in humans. The dopamine D2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of ...
Huang Mu-Chiou +7 more
doaj +2 more sources
Pharmacokinetics of oral bromocriptine in postpartum patients [PDF]
PregnancyIntroduction Cardiomyopathy is a leading cause of maternal morbidity and mortality. A prolactin fragment has been implicated in the pathogenesis, and preliminary data suggest that bromocriptine—a dopamine receptor agonist that inhibits prolactin ...
Rachel Sinkey +7 more
doaj +2 more sources
A Rare Constellation of Peripartum Cardiomyopathy Manifesting With Multiple Thromboembolic Phenomena in a 15-Year-Old. [PDF]
Clin Case RepABSTRACT A 15‐year‐old postpartum primipara presented at 19 days with aphasia, right hemiparesis, chest pain, and dyspnea. Diagnostics confirmed concurrent cardioembolic stroke and pulmonary embolism secondary to peripartum cardiomyopathy (ejection fraction 29%).
Mkama RE +39 more
europepmc +2 more sources
Bromocriptine for idiopathic oligo/asthenospermia.
, 2000 Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology)of unknown cause is common and the need for treatment is felt by patients and doctors alike.
Vail, A.; id_orcid +3 more
core +10 more sources